A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 09 Jul 2017
At a glance
- Drugs Ibrutinib (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pharmacyclics
- 15 Apr 2016 Status changed from not yet recruiting to recruiting.
- 15 Apr 2016 Planned number of patients changed from 231 to 235.
- 15 Apr 2016 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.